Voltage gated sodium and calcium channel blockers for the treatment of chronic inflammatory pain.
The inflammatory response is a natural response of the body that occurs immediately following tissue damage, which may be due to injury, infection or disease. The acute inflammatory response is an essential mechanism that promotes healing and a key aspect is the ensuing pain, which warns the subject to protect the site of injury. Thus, it is common to see a zone of primary sensitization as well as consequential central sensitization that generally, is maintained by a peripheral drive from the zone of tissue injury. Inflammation associated with chronic pain states, such as rheumatoid and osteoarthritis, cancer and migraine etc. is deleterious to health and often debilitating for the patient. Thus there is a large unmet clinical need. The mechanisms underlying both acute and chronic inflammatory pain are extensive and complex, involving a diversity of cell types, receptors and proteins. Among these the contribution of voltage gated sodium and calcium channels on peripheral nociceptors is critical for nociceptive transmission beyond the peripheral transducers and changes in their distribution, accumulation, clustering and functional activities have been linked to both inflammatory and neuropathic pain. The latter has been the main area for trials and use of drugs that modulate ion channels such as carbamazepine and gabapentin, but given the large peripheral drive that follows tissue damage, there is a clear rationale for blocking voltage gated sodium and calcium channels in these pain states. It has been hypothesized that pain of inflammatory origin may evolve into a condition that resembles neuropathic pain, but mixed pains such as low back pain and cancer pain often include elements of both pain states. This review considers the therapeutic potential for sodium and calcium channel blockers for the treatment of chronic inflammatory pain states.
Department of Neuroscience, Physiology and Pharmacology, University College London, Gower Street, London WC1E 6BT, UK. Electronic address: w.rahman@ucl.ac.uk.
Wahida
W
Rahman
Anthony H
AH
Dickenson
D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D015220:Calcium Channels; D002908:Chronic Disease / Q000188:drug therapy; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D051379:Mice; D009437:Neuralgia / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy*; D051381:Rats; D061567:Voltage-Gated Sodium Channel Blockers / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D061567:Voltage-Gated Sodium Channel Blockers
Inflammation; Pain; Voltage gated calcium channel; Voltage gated sodium channel